NF1 and low grade glioma: According to the FDA prescribing information, tovorafenib is approved for the treatment of pediatric patients 6 months of age and older with relapsed or refractory low-grade glioma harboring a BRAF fusion or rearrangement, not associated with neurofibromatosis type 1 (NF–1).